Stirling’s botanical extract, ImmunoXel has already been shown to decrease the duration of the flu in clinical trial participants by 2 – 3 days. The company claims that the ImmunoXel promotes optimized immune system function, and does not rely upon a drug effect against the virus itself.
In the upcoming trial, ImmunoXel effectiveness on the body’s immune system will be tested in people with seasonal flu (including swine flu or 2009 H1N1 flu) both alone, and in tandem with conventional flu drugs. If ImmunoXel’s effect on the immune system is synergistic with antiviral drugs in controlling the flu, such a combination of ImmunoXel as an immune system optimizer, together with an antiviral drug, may be a breakthrough for seasonal flu treatment.
Stirling will launch ImmunoXel under the ‘i-Naturals’ brand in the US.
Under the terms of the agreement governing the upcoming clinical trial, Stirling will support laboratory costs, physician fees, and patient costs. ImmunoXel will be supplied by the company’s Licensor, Ekomed, and antiviral drugs will be supplied by Stirling or its alliance partner, Cipla.